Conference abstractPublished 7 Mar 2016
iRGD, a tumor-penetrating peptide for tumor-specific drug delivery
Sanford Burnham Prebys Medical Discovery Institute, USA
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Delivering cancer drugs specifically to tumors and deep into tumor tissue against the high interstitial pressure is a major hurdle in cancer therapy. The iRGD drug delivery system may provide a solution. The iRGD peptide (CRGDK/RGPD/EC) was identified by phage display against metastatic prostate cancers (Sugahara et al, Cancer Cell, 2009). iRGD carries a tumor-specific RGD motif, which recognizes av integrins that are highly expressed on tumor vasculature and tumor cells, and an RXXK/R CendR motif, which binds to a tissue-penetration receptor neuropilin-1. Importantly, the tissue penetration pathway involves an energy-dependent active transport system, which relies on a mechanism similar to macropinocytosis (Pang et al, Nature Communications, 2014). This unique property allows iRGD to accomplish tumor-penetrating delivery of drugs by simple co-administration (Sugahara et al, Science, 2010). Thus, the therapeutic index of various drugs can be enhanced without any chemical modification of the drugs. In fact, iRGD enhanced tumor-specific accumulation and anti-tumor effects of various types of systemic drugs including small chemicals, nanodrugs, and antibodies in a number of tumor types. Our recent studies have revealed that iRGD alone has anti-metastatic effects when delivered intravenously, providing an additional benefit of using the iRGD system for cancer therapy (Sugahara et al, Molecular Cancer Therapy, 2015). In addition, the iRGD co-administration system is effective not only for systemic cancer therapy, but also for intraperitoneal chemotherapy for peritoneal carcinomatosis (Sugahara et al, Journal of Controlled Release, 2015). A brief overview and recent advances of the iRGD system will be discussed at the meeting
Ask about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- SubjectPharmaceutical Sciences
- SubjectOncology & Cancer
- BylineArticles whose byline prints “Tatiana Hurtado de Mendoza”